Literature DB >> 21893637

Prevalence of polypharmacy exposure among hospitalized children in the United States.

Chris Feudtner1, Dingwei Dai, Kari R Hexem, Xianqun Luan, Talene A Metjian.   

Abstract

OBJECTIVE: To assess the prevalence and patterns of exposure to drugs and therapeutic agents among hospitalized pediatric patients.
DESIGN: Retrospective cohort study.
SETTING: A total of 411 general hospitals and 52 children's hospitals throughout the United States. PATIENTS: A total of 587 427 patients younger than 18 years, excluding healthy newborns, hospitalized in 2006, representing one-fifth of all pediatric admissions in the United States. MAIN OUTCOME MEASURES: Daily and cumulative exposure to drugs and therapeutic agents.
RESULTS: The most common exposures varied by patient age and by hospital type, with acetaminophen, albuterol, various antibiotics, fentanyl, heparin, ibuprofen, morphine, ondansetron, propofol, and ranitidine being among the most prevalent exposures. A considerable fraction of patients were exposed to numerous medications: in children's hospitals, on the first day of hospitalization, patients younger than 1 year at the 90th percentile of daily exposure to distinct medications received 11 drugs, and patients 1 year or older received 13 drugs; in general hospitals, 8 and 12 drugs, respectively. By hospital day 7, in children's hospitals, patients younger than 1 year at the 90th percentile of cumulative exposure to distinct distinct medications had received 29 drugs, and patients 1 year or older had received 35; in general hospitals, 22 and 28 drugs, respectively. Patients with less common conditions were more likely to be exposed to more drugs (P = .001).
CONCLUSION: A large fraction of hospitalized pediatric patients are exposed to substantial polypharmacy, especially patients with rare conditions.

Entities:  

Mesh:

Year:  2011        PMID: 21893637     DOI: 10.1001/archpediatrics.2011.161

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  34 in total

1.  Management and outcomes of pneumonia among children with complex chronic conditions.

Authors:  JoAnna K Leyenaar; Tara Lagu; Meng-Shiou Shieh; Penelope S Pekow; Peter K Lindenauer
Journal:  Pediatr Infect Dis J       Date:  2014-09       Impact factor: 2.129

2.  Prevalence of Clinically Significant Drug-Drug Interactions Across US Children's Hospitals.

Authors:  James W Antoon; Matt Hall; Alison Herndon; Alison Carroll; My-Linh Ngo; Katherine L Freundlich; Justine C Stassun; Patricia Frost; David P Johnson; Swati B Chokshi; Charlotte M Brown; Whitney L Browning; James A Feinstein; Carlos G Grijalva; Derek J Williams
Journal:  Pediatrics       Date:  2020-10-09       Impact factor: 7.124

3.  Pediatric polypharmacy: time to lock the medicine cabinet?

Authors:  Nancy E Morden; David Goodman
Journal:  Arch Pediatr Adolesc Med       Date:  2011-09-05

4.  Incidence of Hospitalization for Vaccine-Preventable Infections in Children Following Solid Organ Transplant and Associated Morbidity, Mortality, and Costs.

Authors:  Amy G Feldman; Brenda L Beaty; Donna Curtis; Elizabeth Juarez-Colunga; Allison Kempe
Journal:  JAMA Pediatr       Date:  2019-03-01       Impact factor: 16.193

5.  Recommendations for Meeting the Pediatric Patient's Need for a Clinical Pharmacist: A Joint Opinion of the Pediatrics Practice and Research Network of the American College of Clinical Pharmacy and the Pediatric Pharmacy Advocacy Group.

Authors:  Varsha Bhatt-Mehta; Marcia L Buck; Allison M Chung; Elizabeth Anne Farrington; Tracy M Hagemann; David S Hoff; Joseph M Larochelle; Rebecca S Pettit; Hanna Phan; Amy L Potts; Katherine P Smith; Richard H Parrish
Journal:  J Pediatr Pharmacol Ther       Date:  2012-07

6.  Epidemiology of Polypharmacy and Potential Drug-Drug Interactions Among Pediatric Patients in ICUs of U.S. Children's Hospitals.

Authors:  Dingwei Dai; James A Feinstein; Wynne Morrison; Athena F Zuppa; Chris Feudtner
Journal:  Pediatr Crit Care Med       Date:  2016-05       Impact factor: 3.624

7.  Variation and outcomes associated with direct hospital admission among children with pneumonia in the United States.

Authors:  JoAnna K Leyenaar; Meng-Shiou Shieh; Tara Lagu; Penelope S Pekow; Peter K Lindenauer
Journal:  JAMA Pediatr       Date:  2014-09       Impact factor: 16.193

Review 8.  The Safety of Drug Therapy in Children.

Authors:  Stefan Wimmer; Antje Neubert; Wolfgang Rascher
Journal:  Dtsch Arztebl Int       Date:  2015-11-13       Impact factor: 5.594

9.  Comparative effectiveness of ceftriaxone in combination with a macrolide compared with ceftriaxone alone for pediatric patients hospitalized with community-acquired pneumonia.

Authors:  Joanna K Leyenaar; Meng-Shiou Shieh; Tara Lagu; Penelope S Pekow; Peter K Lindenauer
Journal:  Pediatr Infect Dis J       Date:  2014-04       Impact factor: 2.129

Review 10.  A Scoping Review of Medications Studied in Pediatric Polypharmacy Research.

Authors:  Alexis E Horace; Negar Golchin; Elia M Pestana Knight; Neal V Dawson; Xuan Ma; James A Feinstein; Hannah K Johnson; Lawrence Kleinman; Paul M Bakaki
Journal:  Paediatr Drugs       Date:  2020-02       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.